BRPI0922305A2 - composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida - Google Patents

composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida

Info

Publication number
BRPI0922305A2
BRPI0922305A2 BRPI0922305A BRPI0922305A BRPI0922305A2 BR PI0922305 A2 BRPI0922305 A2 BR PI0922305A2 BR PI0922305 A BRPI0922305 A BR PI0922305A BR PI0922305 A BRPI0922305 A BR PI0922305A BR PI0922305 A2 BRPI0922305 A2 BR PI0922305A2
Authority
BR
Brazil
Prior art keywords
cyclophosphamide
compositions containing
containing antibodies
antitumor compositions
recognize especially
Prior art date
Application number
BRPI0922305A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI0922305A2 publication Critical patent/BRPI0922305A2/pt
Publication of BRPI0922305B1 publication Critical patent/BRPI0922305B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0922305-3A 2008-11-28 2009-11-27 Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos BRPI0922305B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291119.9 2008-11-28
EP08291119A EP2191843A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PCT/IB2009/055392 WO2010061360A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide

Publications (2)

Publication Number Publication Date
BRPI0922305A2 true BRPI0922305A2 (pt) 2016-06-21
BRPI0922305B1 BRPI0922305B1 (pt) 2022-04-05

Family

ID=40637068

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922305-3A BRPI0922305B1 (pt) 2008-11-28 2009-11-27 Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos

Country Status (30)

Country Link
US (2) US20110305690A1 (pt)
EP (2) EP2191843A1 (pt)
JP (3) JP2012510464A (pt)
KR (1) KR101749770B1 (pt)
CN (1) CN102264387B (pt)
AR (1) AR074221A1 (pt)
AU (1) AU2009321252B2 (pt)
BR (1) BRPI0922305B1 (pt)
CA (1) CA2745012C (pt)
CL (1) CL2011001256A1 (pt)
CO (1) CO6361947A2 (pt)
CR (1) CR20110283A (pt)
EA (2) EA032934B1 (pt)
EC (1) ECSP11011077A (pt)
HK (1) HK1164154A1 (pt)
HN (1) HN2011001426A (pt)
MA (1) MA32894B1 (pt)
ME (1) ME01139B (pt)
MX (1) MX340062B (pt)
MY (1) MY166530A (pt)
NI (1) NI201100104A (pt)
NZ (1) NZ593147A (pt)
PA (1) PA8850201A1 (pt)
PE (1) PE20110822A1 (pt)
SV (1) SV2011003925A (pt)
TW (1) TWI457346B (pt)
UA (1) UA104161C2 (pt)
UY (1) UY32267A (pt)
WO (1) WO2010061360A1 (pt)
ZA (1) ZA201103920B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
MX350540B (es) * 2010-09-27 2017-09-08 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl.
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2014048921A1 (en) 2012-09-25 2014-04-03 Morphosys Ag Combinations and uses thereof
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
TN2016000142A1 (en) * 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MA40608A (fr) 2014-09-09 2016-03-17 Janssen Biotech Inc Polythérapies avec des anticorps anti-cd38
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2016350717B2 (en) 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CA3130132A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CA3160502A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration
JP2024503432A (ja) 2021-01-14 2024-01-25 モルフォシス・アーゲー 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
CN112480257A (zh) * 2005-03-23 2021-03-12 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8551485B2 (en) * 2008-01-23 2013-10-08 Xencor, Inc. Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб

Also Published As

Publication number Publication date
MA32894B1 (fr) 2011-12-01
AU2009321252A1 (en) 2010-06-03
CO6361947A2 (es) 2012-01-20
EA026008B1 (ru) 2017-02-28
TW201024315A (en) 2010-07-01
UA104161C2 (uk) 2014-01-10
ME01139B (me) 2013-03-20
CA2745012A1 (en) 2010-06-03
KR101749770B1 (ko) 2017-06-22
EA032934B1 (ru) 2019-08-30
PA8850201A1 (es) 2010-07-27
JP6018235B2 (ja) 2016-11-02
NZ593147A (en) 2012-12-21
EA201692041A1 (ru) 2017-05-31
JP2017036297A (ja) 2017-02-16
CN102264387A (zh) 2011-11-30
SV2011003925A (es) 2011-10-07
CL2011001256A1 (es) 2012-01-27
PE20110822A1 (es) 2011-11-22
WO2010061360A1 (en) 2010-06-03
UY32267A (es) 2010-06-30
NI201100104A (es) 2011-09-26
MX340062B (es) 2016-06-23
JP6215429B2 (ja) 2017-10-18
CN102264387B (zh) 2015-04-08
EP2191843A1 (en) 2010-06-02
JP2015120729A (ja) 2015-07-02
MY166530A (en) 2018-07-10
CA2745012C (en) 2020-09-15
CR20110283A (es) 2011-09-20
HN2011001426A (es) 2014-01-13
US20170056496A1 (en) 2017-03-02
US20110305690A1 (en) 2011-12-15
JP2012510464A (ja) 2012-05-10
TWI457346B (zh) 2014-10-21
MX2011005538A (es) 2011-10-10
KR20110096552A (ko) 2011-08-30
EA201100869A1 (ru) 2011-10-31
EP2370097A1 (en) 2011-10-05
EP2370097B1 (en) 2019-01-09
AU2009321252B2 (en) 2016-06-09
ECSP11011077A (es) 2011-07-29
HK1164154A1 (en) 2012-09-21
ZA201103920B (en) 2012-09-26
AR074221A1 (es) 2010-12-29
BRPI0922305B1 (pt) 2022-04-05

Similar Documents

Publication Publication Date Title
BRPI0922305A2 (pt) composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida
BRPI0921864A2 (pt) combinações antitumor contendo anticorpos que reconhecem especificamente cd38 e melfalano
BRPI0922304A2 (pt) combinações antitumorais contendo anticorpos que especificamente reconhecem cd38 e vincristina
PH12017501298A1 (en) Pesticidal compositions and processes related thereto
IL213118A (en) Combinations of tumors that include antibodies that specifically recognize the 38cd cyclophosphamide
BRPI0914745A2 (pt) composição nutricional
BRPI0817779A2 (pt) Processamento de gás de hidrocarboneto
BRPI0915824A2 (pt) Composição nutricional contendo mistura de oligossacarídeos
AP2010005424A0 (en) Assays.
BRPI0813892A2 (pt) composições que compreendem antígenos pneumococcal
BRPI0814745A2 (pt) Composição de produto.
ES2703158T8 (es) Composiciones farmacéuticas que comprenden oxi-hidróxido de hierro
ES2628203T8 (es) Composiciones antitranspirantes
BRPI0922005A2 (pt) composições antiespumantes.
IT1394472B1 (it) Tavolo per riunioni.
BR112012003977A2 (pt) composições que induzem ajuda de célula t
BRPI0920653A2 (pt) embalagem
BRPI0907925A2 (pt) Ativadores de glicoquinase.
BRPI0923428A2 (pt) refinaria de gás integrada
BRPI0906812A2 (pt) Mitigação de reluzência do lcd.
BR112012012890A2 (pt) misturas estabilizadas que contêm modificadores de fricção.
DE602008004219D1 (de) Packung für rauchartikel
IL219470A (en) Antibacterial antibody, preparations containing it and its uses
BRPI0906828A2 (pt) Embalagem
HK1222096A1 (zh) 含有安石榴苷的營養組合物

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.